Page 61 - 2020_08-Haematologica-web

AvWS focused for hematologists
Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol. 1990;35(2):114-117.
34. Scrobohaci ML, Daniel MT, Levy Y, Marolleau JP, Brouet JC. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol. 1993;84(3):471-475.
35. Mital A, Prejzner W, Bieniaszewska M, Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015;125(12):914-920.
36. Mital A, Prejzner W, S´wia˛tkowska- Stodulska R, Hellmann A. Factors predispos- ing to acquired von Willebrand syndrome during the course of polycythemia vera - ret- rospective analysis of 142 consecutive cases. Thromb Res. 2015;136(4):754-757.
37. Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential throm- bocythemia and polycythemia vera. Eur J Intern Med. 2017;41:49-54.
38. Mital A, Prejzner W, Hellmann A. Acquired von Willebrand syndrome during systemic mastocytosis: an analysis of 21 cases. Pol Arch Intern Med. 2018;128(7):491-493.
39. Federici AB. Acquired von Willebrand syn- drome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost. 2008;6(4):565-568.
40. Favaloro EJ, Facey D, Grispo L. Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity of sample preparation and differential recognition of high molecu- lar weight VWF forms. Am J Clin Pathol. 1995;104(3):264-271.
41. van Genderen PJ, Boertjes RC, van Mourik
JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost. 1998;80(3):495-498.
51. Federici AB. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome. Hum Immunol. 2005;66(4):422-430.
52. Federici AB, Rossi V, Sacchi E, Franchini M. Are intravenous immunoglobulins really inappropriate in acquired von Willebrand syndrome? Blood Transfus. 2012;10(3):402-
42. Eikenboom J, Federici AB, Dirven RJ, et al; MCMDM-1VWD Study Group. VWF
propeptide and ratios between VWF, VWF
propeptide, and FVIII in the characterization
of type 1 von Willebrand disease. Blood. 403.
2013;121(12):2336-2339.
43. Fricke WA, Brinkhous KM, Garris JB,
Roberts HR. Comparison of inhibitory and binding characteristics of an antibody caus- ing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood. 1985;66(3):562-569.
44. Mannucci PM, Lombardi R, Bader R, et al. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood. 1984;64(3):614-621.
45. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003;9(3):303-308.
46. Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Investig Drugs. 2000;9(2):347-354.
47. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25): 6777-6785.
53. Stone ME, Mazzeffi M, Derham J, Korshin A. Current management of von Willebrand disease and von Willebrand syndrome. Curr Opin Anaesthesiol. 2014;27(3):353-358.
54. Michiels JJ, van Vliet HH. Acquired von Willebrand disease in monoclonal gammap- athies: Effectiveness of high-dose intra- venous gamma globulin. Clin Appl Thromb Hemost. 1999;5(3):152-157.
55. Colella MP, Duarte GC, Marques JF Jr, De Paula EV. Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome. Haemophilia. 2012;18(3):e188-191.
56. Friederich PW, Wever PC, Briët E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy- resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol. 2001;66(4):292-294.
57. Franchini M, Veneri D, Lippi G. The use of recombinant activated factor VII in congeni- tal and acquired von Willebrand disease. Blood Coagul Fibrinolysis. 2006;17(8):615-
48. Franchini M. The use of desmopressin as a 619.
hemostatic agent: a concise review. Am J
Hematol. 2007;82(8):731-735.
49. Biguzzi E, Siboni SM, Peyvandi F. Acquired
von Willebrand syndrome and response to desmopressin. Haemophilia. 2018;24(1):e25- e28
50. Franchini M, Mannucci PM. The never end- ing success story of tranexamic acid in acquired bleeding. Haematologica. 2020;105 (5):1201-1205.
58. Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treat- ed with recombinant factor VIIa during thy- roidectomy. Thromb Haemost. 2004;92(3): 666-667.
59. Karger R, Weippert-Kretschmer M, Budde U, Kretschmer V. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Blood Coagul Fibrinolysis. 2011;22(2):144-147.
haematologica | 2020; 105(8)
2037